8 results on '"intensive regimen"'
Search Results
2. Improved Prognosis in ALL with Modified BFM Protocols — Preliminary Results from Turkey
- Author
-
Sağlamer, L., Ulukutlu, L., Yıldız, İ., Büchner, T., editor, Hiddemann, W., editor, Wörmann, B., editor, Schellong, G., editor, and Ritter, J., editor
- Published
- 1994
- Full Text
- View/download PDF
3. Bone Marrow Transplantation for Children with Acute Lymphoblastic Leukemia Failing Conventional Therapy
- Author
-
Boulad, F., Black, P., Emanuel, D., Gillio, A., Kernan, N. A., Small, T. N., O’Reilly, R. J., Büchner, T., editor, Hiddemann, W., editor, Wörmann, B., editor, Schellong, G., editor, and Ritter, J., editor
- Published
- 1994
- Full Text
- View/download PDF
4. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
- Author
-
Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Troncone, Giancarlo, Dal Mas, Antonella, Coletti, Gino, Fr‚bourg, Thierry, Sabourin, Jean Christophe, Tosi, Mario, Ficorella, Corrado, and Ricevuto, Enrico
- Subjects
- *
COLON cancer patients , *BEVACIZUMAB , *CANCER chemotherapy , *METASTASIS , *LIVER surgery - Abstract
Background: Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated. Methods: Tumoral and metastatic samples were screened for KRAS codon 12 and 13 and BRAF mutations by SNaPshot and/or direct sequencing. Fit MCRC patients <75 years were consecutively treated with FIr-B/FOx regimen: weekly 12-h timed flat-infusion/5-fluorouracil (TFI 5-FU) 900 mg/m2, days 1, 2, 8, 9, 15, 16, 22 and 23; irinotecan (CPT-11) 160 mg/m2 plus BEV 5 mg/kg, days 1, 15; oxaliplatin (OXP) 80 mg/m2, days 8, 22; every 4 weeks. MCRC patients were classified as L-L and O/MM. Activity and efficacy were evaluated and compared using log-rank test. Results: In all, 59 patients were evaluated: 31 KRAS wild-type (53%), 28 KRAS mutant (47%). At 21.5 months median follow-up, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were, respectively: KRAS wild-type 90%, 14 months, 38 months; KRAS mutant 67%, 11 months, 20 months. PFS and OS were not significantly different. PFS and OS were significantly different in L-L compared to O/MM evaluable patients. In KRAS wild-type patients, clinical outcome of 12 L-L compared to 18 O/MM was significantly different: PFS 21 versus 12 months and OS 47 versus 28 months, respectively. In KRAS mutant patients, the clinical outcome of 13 L-L compared to 14 O/MM was not significantly different: PFS 11 months equivalently and OS 39 versus 19 months, respectively. Conclusions: The KRAS genotype wild-type and mutant does not significantly affect different clinical outcomes for MCRC patients treated with the first-line FIr-B/FOx intensive regimen. KRAS wild-type patients with L-L disease may achieve a significantly prolonged clinical outcome due to integration with secondary liver surgery, with respect to KRAS mutant patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. THROMBOTIC THROMBOCYTOPENIC PURPURA IN A CASE OF SCLERODERMA RENAL CRISIS TREATED WITH TWICE-DAILY THERAPEUTIC PLASMA EXCHANGE.
- Author
-
Kfoury Baz, Elizabeth M., Mahfouz†, Rami A. R., Masri, Abdel Fattah M., and Jamaleddine, Ghassan W.
- Subjects
- *
THROMBOTIC thrombocytopenic purpura , *SCLERODERMA (Disease) , *KIDNEY diseases , *PLASMA exchange (Therapeutics) - Abstract
We report the rare complication of thrombotic thrombocytopenic purpura (TTP) in an elderly patient with the uncommon scleroderma renal crisis (SRC) at the advanced age of 85 years. Initially, she was treated by standard daily one and a half plasma volume therapeutic plasma exchange (TPE), in combination with steroid therapy. Due to an unsatisfactory clinical response, she was consequently, treated by an intensive twice-daily one and a half plasma volume TPE regimen. Although there was an increase in the platelet count, a 7-day course of the intensive regimen did not elicit further propitious laboratory test results or a clinical improvement and the patient expired secondary to the pulmonary and cardiac conditions related to SRC. Intensive TPE administration has been advocated in few specific patients who are refractory to standard daily treatment. The unfavorable outcome in this case may be attributed to the multiple complications associated with her primary disorder. In conclusion, we observed intensive twice-daily TPE to increase temporarily the platelet count, but not to be of benefit in a patient with SRC and multiple organ failure. The two TPE regimens and outcomes are compared and the pathogenesis of TTP and scleroderma are discussed. †Resident [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
6. High-dose Chemotherapy of Small-Cell Lung Cancer With and Without Bone Marrow Transplantation
- Author
-
Sculier, J. P., Klastersky, J., McGuire, William L., editor, and Hansen, Heine H., editor
- Published
- 1989
- Full Text
- View/download PDF
7. The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
- Author
-
Gemma Bruera, Alessandra Tessitore, Corrado Ficorella, Enrico Ricevuto, Edoardo Alesse, Antonio Russo, Katia Cannita, Bruera, G., Cannita, K., Tessitore, A., Russo, A., Alesse, E., Ficorella, C., and Ricevuto, E.
- Subjects
Oncology ,Vascular Endothelial Growth Factor A ,Pathology ,A+mutation%22">KRAS c.35 G>A mutation ,Colorectal cancer ,medicine.medical_treatment ,Mutant ,Intensive regimen ,Colorectal Neoplasm ,medicine.disease_cause ,Exon ,Mutation Rate ,Antineoplastic Combined Chemotherapy Protocols ,Neoplasm Metastasis ,Proto-Oncogene Protein ,Metastatic colorectal cancer ,Hematology ,Exons ,Prognosis ,Neoplasm Metastasi ,Bevacizumab ,Treatment Outcome ,Disease Progression ,Biomarker (medicine) ,KRAS ,Colorectal Neoplasms ,Human ,medicine.drug ,medicine.medical_specialty ,Genotype ,Prognosi ,Antibodies, Monoclonal, Humanized ,Proto-Oncogene Proteins p21(ras) ,Internal medicine ,Proto-Oncogene Proteins ,medicine ,Humans ,Chemotherapy ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Biomarker ,ras Protein ,medicine.disease ,Regimen ,Mutation ,ras Proteins ,Intensive regimens ,Biomarkers ,Geriatrics and Gerontology ,business - Abstract
Bevacizumab-containing chemotherapy differently predict increased efficacy in KRAS exon 2 mutant and wild-type metastatic colorectal cancer (MCRC) patients. Mutant compared to wild-type status did not significantly affect progression-free survival (PFS) and overall survival (OS) in patients fit for first line bevacizumab-containing FIr-B/FOx regimen, and after progression. In patients unfit for intensive regimens, mutant status significantly affected PFS, while not OS. Codon 12 KRAS mutations differentially affect GTPase function, and confer worse clinical behaviour. Prognostic relevance of the prevalent c.35 G. >. A KRAS mutation was retrospectively evaluated. Fit c.35 G. >. A mutant patients showed significantly worse OS compared to wild-type and to other mutant. After progression and in unfit patients, c.35 G. >. A mutation affected significantly worse PFS and OS. c.35 G. >. A mutant status does not significantly affect worse PFS in patients fit for first line FIr-B/FOx, and it may depend upon effectiveness of anti-VEGF-containing intensive regimen.
- Published
- 2015
8. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
- Author
-
Aude Lamy, Enrico Ricevuto, Mario Tosi, Thierry Frebourg, Antonella Dal Mas, Gino Coletti, Giancarlo Troncone, Katia Cannita, Corrado Ficorella, Daniela Di Giacomo, J.C. Sabourin, Gemma Bruera, Medical Oncology, Università degli Studi dell'Aquila (UNIVAQ)-S. Salvatore Hospital, Department of Experimental Medicine, Università degli Studi dell'Aquila (UNIVAQ), laboratoire de Génétique Somatique des Tumeurs, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Department of Biomorphologic and Functional Sciences, Università degli studi di Napoli Federico II, Pathology Department, S. Salvatore Hospital, Génétique médicale et fonctionnelle du cancer et des maladies neuropsychiatriques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Anatomie et Cytologie Pathologique [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), BMC, Ed., Università degli Studi dell'Aquila = University of L'Aquila (UNIVAQ)-S. Salvatore Hospital, Università degli Studi dell'Aquila = University of L'Aquila (UNIVAQ), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, University of Naples Federico II = Università degli studi di Napoli Federico II, Bruera, G, Cannita, K, Di Giacomo, D, Lamy, A, Troncone, Giancarlo, Dal Mas, A, Coletti, G, Frebourg, T, Sabourin, Jc, Tosi, M, Ficorella, C, and Ricevuto, E.
- Subjects
Oncology ,Male ,Colorectal cancer ,triplet chemotherapy plus bevacizumab ,lcsh:Medicine ,Disease ,medicine.disease_cause ,0302 clinical medicine ,Genotype ,KRAS mutations ,Infusions, Intravenous ,Medicine(all) ,0303 health sciences ,metastatic colorectal cancer ,General Medicine ,Middle Aged ,Prognosis ,intensive regimen ,3. Good health ,Bevacizumab ,Treatment Outcome ,030220 oncology & carcinogenesis ,[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,Drug Therapy, Combination ,Female ,KRAS ,Colorectal Neoplasms ,medicine.drug ,Research Article ,Adult ,medicine.medical_specialty ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,Internal medicine ,Proto-Oncogene Proteins ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,medicine ,Humans ,neoplasms ,030304 developmental biology ,Aged ,business.industry ,lcsh:R ,medicine.disease ,digestive system diseases ,Oxaliplatin ,Irinotecan ,Regimen ,disease extension ,ras Proteins ,business - Abstract
Background Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated. Methods Tumoral and metastatic samples were screened for KRAS codon 12 and 13 and BRAF mutations by SNaPshot and/or direct sequencing. Fit MCRC patients 2, days 1, 2, 8, 9, 15, 16, 22 and 23; irinotecan (CPT-11) 160 mg/m2 plus BEV 5 mg/kg, days 1, 15; oxaliplatin (OXP) 80 mg/m2, days 8, 22; every 4 weeks. MCRC patients were classified as L-L and O/MM. Activity and efficacy were evaluated and compared using log-rank test. Results In all, 59 patients were evaluated: 31 KRAS wild-type (53%), 28 KRAS mutant (47%). At 21.5 months median follow-up, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were, respectively: KRAS wild-type 90%, 14 months, 38 months; KRAS mutant 67%, 11 months, 20 months. PFS and OS were not significantly different. PFS and OS were significantly different in L-L compared to O/MM evaluable patients. In KRAS wild-type patients, clinical outcome of 12 L-L compared to 18 O/MM was significantly different: PFS 21 versus 12 months and OS 47 versus 28 months, respectively. In KRAS mutant patients, the clinical outcome of 13 L-L compared to 14 O/MM was not significantly different: PFS 11 months equivalently and OS 39 versus 19 months, respectively. Conclusions The KRAS genotype wild-type and mutant does not significantly affect different clinical outcomes for MCRC patients treated with the first-line FIr-B/FOx intensive regimen. KRAS wild-type patients with L-L disease may achieve a significantly prolonged clinical outcome due to integration with secondary liver surgery, with respect to KRAS mutant patients.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.